# China NMPA Drug Inspection - Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd. - Amomum villosum

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-taiyuan-traditional-chinese-medicine-pieces-co-ltd/649eee35-66c3-4630-9fa6-a0ecaa7bdffe/
Source feed: China

> China NMPA drug inspection for Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd. published December 08, 2020. Drug: Amomum villosum. This document from the Shanxi Provincial Drug Administration, announced on December 8, 2020, details significant quality

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Shanxi Provincial Drug Administration Regarding 7 Batches of Drugs That Failed to Meet Regulations
- Company Name: Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2020-12-08
- Drug Name: Amomum villosum
- Inspection Finding: The properties did not meet the requirements.
- Action Taken: Risk control measures such as suspension of sales and use, and recall.
- Summary: This document from the Shanxi Provincial Drug Administration, announced on December 8, 2020, details significant quality control failures in several drug products. Multiple pharmaceutical and traditional Chinese medicine companies were cited for non-compliance following product sampling. Shanxi Lifeng Huarui Pharmaceutical Co., Ltd. produced a batch of hydrochlorothiazide tablets that failed the dissolution rate test, which could impact drug absorption. Traditional Chinese medicine manufacturers, including Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd., Anhui Wugeng Traditional Chinese Medicine Pieces Co., Ltd. (for two distinct products), and Anhui Runbang Traditional Chinese Medicine Pieces Co., Ltd., were found to have batches of herbal remedies (Akebia stem, Lysimachia christinae, Acanthopanax bark, and Amomum villosum) that failed appearance tests, indicating potential issues with raw materials or processing. Additionally, Jiuquan Peifeng Traditional Chinese Medicine Ecological Planting and Processing Co., Ltd.'s Scrophularia root failed total ash and content determination tests. Operating under the regulatory framework of the National Medical Products Administration (NMPA), the Shanxi Provincial Drug Administration investigated these issues. As required actions, the implicated enterprises and units implemented risk control measures, including suspending sales and use, and initiating product recalls to ensure public safety and adherence to quality standards.

Company: https://www.globalkeysolutions.net/companies/anhui-taiyuan-traditional-chinese-medicine-pieces-co-ltd/2391fa22-687e-48e5-8e7e-c896278012ad/